Announcement
Pemberton supports the refinancing of leading cancer care provider GenesisCare UK
GenesisCare UK is the UK’s leading independent specialist cancer care provider and currently operates 14 specialist outpatient centres. It is driven by transforming cancer care with advanced diagnostics, medical oncology, radiotherapy, and theranostics.
In addition, GenesisCareUK works with universities and leading clinicians around the world, to research and design new and better ways to treat cancers and has a growing UK clinical trials programme to support bringing new therapies to more patients.
The transaction, which provides GenesisCare UK with the option of drawing on funds of up to £140m, follows a successful restructuring of the global GenesisCare Group, which concluded in February 2024. The new lending facilities will be provided by Pemberton Asset Management, a leading European private debt manager, and Barclays.
We are delighted to be partnering with GenesisCare UK, who are at the forefront of cancer treatment in the UK. The Group’s use of advanced treatment methods and well invested facilities enable their clinicians to deliver the highest standard of care for patients. We look forward to supporting the team in realising their growth aspirations over the coming years.
– Richard Meehan, Managing Director, Origination
We are delighted to have completed our refinancing, which reinforces the confidence we and our partners have in the GenesisCare business and our growth strategy. Our focus remains on expanding our network of world class cancer care centres and delivering the highest possible standards of care to patients with a suspected or confirmed cancer diagnosis.
– Justin Hely, CEO (UK & Europe), GenesisCare
